A clearer view of the molecular complexity of clear cell renal cell carcinoma

Ian J Frew1, Holger Moch

  • 1Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich CH-8057, Switzerland;

Annual Review of Pathology
|November 12, 2014
PubMed

Insights

The von Hippel-Lindau (VHL) gene mutation drives clear cell renal cell carcinoma (ccRCC). Understanding VHL protein (pVHL) functions and tumor genetic diversity is key to ccRCC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer.
  • The von Hippel-Lindau (VHL) tumor suppressor gene is frequently mutated early in ccRCC development.

Purpose of the Study:

  • To review recent advances in understanding VHL tumor suppressor protein (pVHL) functions.
  • To explore how VHL dysregulation contributes to ccRCC initiation and progression.
  • To discuss the role of genetic and epigenetic alterations in ccRCC.

Main Methods:

  • Review of recent scientific literature on VHL and ccRCC.
  • Analysis of genetic and epigenetic alterations in ccRCC tumors.
  • Discussion of VHL protein functions and their impact on tumorigenesis.

Main Results:

  • VHL gene mutations are an early event in most ccRCC cases.
  • pVHL has multiple hypoxia-inducible factor α-dependent and -independent functions.
  • ccRCC exhibits extensive inter- and intratumoral genetic diversity, suggesting distinct molecular subtypes.
  • Genetic and epigenetic alterations cooperate with loss of pVHL function in ccRCC development.

Conclusions:

  • Dysregulation of pVHL contributes significantly to ccRCC initiation and progression.
  • ccRCC can be viewed as a spectrum of diseases defined by specific genetic alteration patterns.
  • Further research into these alterations is crucial for targeted ccRCC therapies.

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
7.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Renal Corpuscle01:20

Renal Corpuscle

The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
9.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.2K